US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

February 02, 2022

Eli Lilly and Company v. Novartis Pharma AG

Track this case

Case Number:

22-1094

Court:

Appellate - 4th Circuit

Nature of Suit:

3890 Other Statutory Actions

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. June 16, 2022

    4th Circ. Denies Eli Lilly's Discovery Bid In Novartis IP Feud

    The Fourth Circuit on Thursday affirmed a Virginia district court's decision denying Eli Lilly's discovery bid related to Novartis' European patent suit over Eli Lilly's psoriasis drug Taltz, agreeing that Novartis didn't reside in the district and thus couldn't be forced to hand over evidence for use in foreign proceedings.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login